Crossing barriers: the burden of inflammatory bowel disease across Western Europe.

"MJB has received grants and travel expenses from Vifor International and Tillotts Pharma, outside of the submitted work. BG has served as a speaker for AbbVie, Janssen, Takeda and Galapagos and has worked as an advisor for AbbVie and Galapagos. BV has received research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sosei Heptares and Takeda. He has received speaker’s fees from AbbVie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris. He also received consultancy fees from AbbVie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Mylan, Inotrem, Ipsos, Janssen, Pfizer, Progenity, Sandoz, Sosei Heptares, Takeda, Tillotts Pharma and Viatris. DB is on the advisory board or consultant for AbbVie, Amgen, Arena, Atheneum, BNG Service GmbH, Bristol Myers Squibb, CED-Service GmbH, Celltrion, Doctorflix, DGVS, Diaplan, Else Kröner-Fresenius Foundation, Falk Foundation, Galapagos, Gastro Today, Guidepoint, Impulze, Ferring, Janssen Cilag, Lilly, Medical Tribune, MedTriX, MSD, Mylan, Onkowissen, Pharmacosmos, Pfizer, Roche, Sandoz, Takeda, Tetrameros, Thieme, Tillotts Pharma, UCB Biopharma, Viatris and Vifor Pharma. IC-S has received Research Grants/Consultant fees from AbbVie, Bristol Myers Squibb, Janssen, Ferring, Tillotts Pharma, Takeda and Eli Lilly. The rest of the authors do not have anything to declare."

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."